Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Placebo

Core clinician-reference fields are available or not applicable.

Participants received metformin for 3 months followed by a washout period and then switched to placebo for another 3 months.

Metformin

Participants were randomly assigned in a 1:1 ratio to receive either metformin or placebo for 3 months. Then, after a 1-month washout period (116 half-lives for metformin), the medication was changed to the other treatment for another 3 months.

Participants received placebo for 3 months followed by a washout period and then switched to metformin for another 3 months.

Metformin improves glycemic control in heart failure patients

Not extracted from the authoritative source.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: comparator.

Control group receiving metformin tablets daily for 45 days.

Group A (Control)

In Group A (Control), metformin tablets (500 mg) will be prescribed daily once before lunch with plain water for 45 consecutive days.

Interventional group receiving Nimba-Amalakyadi formulation twice daily for 45 days.

Group B (Interventional group)

In Group B (Interventional group), the Nimba-Amalakyadi formulation will be prescribed 5 grams twice daily with an empty stomach (ie, 7 AM-5 PM) with lukewarm water for 45 consecutive days.

Authoritative quality diagnostic: invalid or missing value.

Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes

Postmeal Metformin Group

Participants received metformin before meals for 4 weeks.

Premeal Metformin Group

All participants were randomly assigned to receive immediate-release metformin either 30–60 min before or immediately after meal for 4 weeks.

Participants received metformin after meals for 4 weeks.

Premeal metformin improves postmeal glucose control in diabetes.

Source evidence could not be resolved sufficiently for this field.

Clinician-reference record is usable with limitations in: design, comparator, risk_of_bias.

Patients receiving metformin as monotherapy.

Metformin group (Group M)

Patients receiving metformin 1000 mg once daily were taken in Group M.

Patients receiving metformin plus ranolazine.

Metformin plus ranolazine group (Group M+R)

Patients receiving metformin 1000 mg once daily plus ranolazine were enrolled in Group M+R.

Authoritative quality diagnostic: source evidence unresolved.

Ranolazine improves glycaemic control when added to metformin in T2DM patients

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 2 studies described adult participants.

1 of 2 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Structured population data were available for 3 of 3 supporting studies. 1 study described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved, usual_care.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: other, usual_care.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 3 studies described adult participants.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Evidence uses heterogeneous comparison contexts: placebo, unknown_unresolved, usual_care.

Structured population data were available for 6 of 6 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 3 studies described adult participants.

3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

3 of 6 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. Diabetes type was heterogeneous: 2 studies with type 2 diabetes, 1 studies with type 1 diabetes. 3 studies described adult participants.

4 of 4 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 7 of 7 supporting studies. Diabetes type was heterogeneous: 4 studies with type 2 diabetes, 1 studies with type 1 diabetes. 5 studies described adult participants.

3 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.

2 studies contain conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Structured population data were available for 9 of 9 supporting studies. Diabetes type was heterogeneous: 4 studies with type 1 diabetes, 2 studies with type 2 diabetes. 7 studies described adult participants.

Metformin

Evidence signal

Evidence snapshot

Clinical conclusion

Observed effects

Evidence composition

Consistency

Population and applicability

Limitations

Supporting evidence